Middle East & Africa Genotyping Market Forecast to 2031 - Regional Analysis - by Product Type, Technology, Application, and End user

Description

List of Tables

The Middle East & Africa genotyping market was valued at US$ 1,218.66 million in 2023 and is expected to reach US$ 4,275.51 million by 2031; it is estimated to record a CAGR of 17.0% from 2023 to 2031.

Increasing Popularity of Personalized Medicine Bolsters Middle East & Africa Genotyping Market

According to the National Health Service of England, personalized medicine is the medical treatment tailored to the unique traits of each patient. The method is based on scientific advancements that provide an understanding of a person's unique genetic and molecular profile that contributes to their susceptibility to diseases as well as helps determine the safest and most effective medical treatments. Genomic medicine, guided by each person's unique genetic, clinical, and environmental information, is a fundamental component of personalized medicine. The fundamentals of personalized medicine involve the standardization, development, and integration of various essential tools into health systems and clinical workflows for the whole-genome studies of transcription, sequence variation, proteins, and metabolites. Health risk assessment, family health history, and clinical decision assistance for complex risk and predictive information are combined with genomic data to detect individual risks and guide clinical treatment, laying the groundwork for a more informed and effective patient care approach.

DNA-based risk assessment for common complex diseases, genome-guided therapy, dose selection, and molecular signatures for cancer diagnosis and prognosis are examples of genome information has already enabled personalized health care. The integration of personalized medicine with healthcare can aid in more precise diagnoses, enable the prediction of disease risk before the occurrence of symptoms and provide individualized treatment plans with maximum safety and efficiency. Genotype data can be utilized as a guideline to determine the correct warfarin dose. The Clinical Pharmacogenetics Implementation Consortium has developed genotype-based drug guidelines to assist physicians in optimizing pharmacological therapies based on genetic test results. Genomic analysis of tumors can help tailor therapeutic approaches for treating individuals with hereditary cancer.

Although scientific discoveries related to personalized medicine are making their way from labs to clinics, the widespread acceptance of personalized medicine necessitates significant changes in regulatory, reimbursement procedures, and legislative privacy laws for rapid adoption of these medicines. Thus, increasing awareness and popularity of personalized medicine due to ongoing research and use of genome editing techniques is expected to act as a trend for growth of the genotyping market.

Middle East & Africa Genotyping Market Overview

The genotyping market growth in the Middle East & Africa is attributed to factors such as significant advancements in healthcare facilities, the high adoption rate of robotics in therapy, and geographic expansion efforts by market players. Moreover, the rising incidence of cancer, growing investments in the healthcare sector from several private and government institutions and increasing collaborations with hospitals from developed regions are expected to boost the genotyping market growth in the Middle East & Africa during the forecast period.

Middle East & Africa Genotyping Market Revenue and Forecast to 2031 (US$ Million)

Middle East & Africa Genotyping Market Segmentation

The Middle East & Africa genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the Middle East & Africa genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the Middle East & Africa genotyping market is segmented into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the Middle East & Africa genotyping market is bifurcated into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the Middle East & Africa genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Middle East & Africa genotyping market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, Thermo Fisher Scientific Inc, BioTek Instruments Inc, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are among the leading companies operating in the Middle East & Africa genotyping market.

Product Code: BMIRE00025970

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Middle East & Africa Genotyping Market Landscape

4.1 Overview
4.2 Global Market Share Analysis
- 4.2.1 Global Market Share (%) of Leading Players for NGS Library Preparation
- 4.2.2 Global Market Share (%) of Leading Player for Genotyping
- 4.2.3 Global Market Share (%) of Leading Player for Gene Expression

5. Middle East & Africa Genotyping Market - Key Market Dynamics

5.1 Market Drivers:
- 5.1.1 Use in Diagnosis of Genetic and Rare Diseases
- 5.1.2 Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry
5.2 Market Restraints
- 5.2.1 High Cost of Equipment and Shortage of Skilled Professionals
5.3 Market Opportunities
- 5.3.1 Expanding Range of Applications
5.4 Future Trends
- 5.4.1 Increasing Popularity of Personalized Medicine
5.5 Impact of Drivers and Restraints:

6. Genotyping Market - Middle East & Africa Analysis

6.1 Genotyping Market Revenue (US$ Million), 2021-2031

7. Middle East & Africa Genotyping Market Analysis - by Product Type

7.1 Instruments
- 7.1.1 Overview
- 7.1.2 Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Reagents and Kits
- 7.2.1 Overview
- 7.2.2 Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Bioinformatics
- 7.3.1 Overview
- 7.3.2 Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Genotyping Services
- 7.4.1 Overview
- 7.4.2 Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

8. Middle East & Africa Genotyping Market Analysis - by Technology

8.1 Microarray
- 8.1.1 Overview
- 8.1.2 Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Capillary Electrophoresis
- 8.2.1 Overview
- 8.2.2 Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Sequencing
- 8.3.1 Overview
- 8.3.2 Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Polymerase Chain Reaction (PCR)
- 8.4.1 Overview
- 8.4.2 Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Matrix-Assisted Laser Desorption / MALDI-TOF
- 8.5.1 Overview
- 8.5.2 Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Other Technologies
- 8.6.1 Overview
- 8.6.2 Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

9. Middle East & Africa Genotyping Market Analysis - by Application

9.1 Pharmacogenomics
- 9.1.1 Overview
- 9.1.2 Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Diagnostics and Personalized Medicine
- 9.2.1 Overview
- 9.2.2 Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Animal Genetics
- 9.3.1 Overview
- 9.3.2 Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Agricultural Biotechnology
- 9.4.1 Overview
- 9.4.2 Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Other Applications
- 9.5.1 Overview
- 9.5.2 Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

10. Middle East & Africa Genotyping Market Analysis - by End-user

10.1 Pharmaceutical and Biopharmaceutical Companies
- 10.1.1 Overview
- 10.1.2 Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Diagnostic and Research Laboratories
- 10.2.1 Overview
- 10.2.2 Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Academic Institutes
- 10.3.1 Overview
- 10.3.2 Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
10.4 Other End Users
- 10.4.1 Overview
- 10.4.2 Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

11. Middle East & Africa Genotyping Market - Country Analysis

11.1 Middle East & Africa
- 11.1.1 Middle East & Africa: Genotyping Market - Revenue and Forecast Analysis - by Country
  - 11.1.1.1 Saudi Arabia: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.1.1 Saudi Arabia: Genotyping Market Breakdown, by Product Type
    - 11.1.1.1.2 Saudi Arabia: Genotyping Market Breakdown, by Technology
    - 11.1.1.1.3 Saudi Arabia: Genotyping Market Breakdown, by Application
    - 11.1.1.1.4 Saudi Arabia: Genotyping Market Breakdown, by End-user
  - 11.1.1.2 South Africa: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.2.1 South Africa: Genotyping Market Breakdown, by Product Type
    - 11.1.1.2.2 South Africa: Genotyping Market Breakdown, by Technology
    - 11.1.1.2.3 South Africa: Genotyping Market Breakdown, by Application
    - 11.1.1.2.4 South Africa: Genotyping Market Breakdown, by End-user
  - 11.1.1.3 United Arab Emirates: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.3.1 United Arab Emirates: Genotyping Market Breakdown, by Product Type
    - 11.1.1.3.2 United Arab Emirates: Genotyping Market Breakdown, by Technology
    - 11.1.1.3.3 United Arab Emirates: Genotyping Market Breakdown, by Application
    - 11.1.1.3.4 United Arab Emirates: Genotyping Market Breakdown, by End-user
  - 11.1.1.4 Rest of Middle East & Africa: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.4.1 Rest of Middle East & Africa: Genotyping Market Breakdown, by Product Type
    - 11.1.1.4.2 Rest of Middle East & Africa: Genotyping Market Breakdown, by Technology
    - 11.1.1.4.3 Rest of Middle East & Africa: Genotyping Market Breakdown, by Application
    - 11.1.1.4.4 Rest of Middle East & Africa: Genotyping Market Breakdown, by End-user

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in Genotyping Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 QIAGEN NV
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Merck KGaA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Thermo Fisher Scientific Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 BioTek Instruments, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Illumina Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Danaher Corp
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bio-Rad Laboratories Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 GE HealthCare Technologies Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Standard BioTools Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Laboratory Corp of America Holdings
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 Beckman Coulter Inc
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
- 13.12.6 Key Developments
13.13 BGI
- 13.13.1 Key Facts
- 13.13.2 Business Description
- 13.13.3 Products and Services
- 13.13.4 Financial Overview
- 13.13.5 SWOT Analysis
- 13.13.6 Key Developments
13.14 Takara Bio Inc
- 13.14.1 Key Facts
- 13.14.2 Business Description
- 13.14.3 Products and Services
- 13.14.4 Financial Overview
- 13.14.5 SWOT Analysis
- 13.14.6 Key Developments
13.15 DiaSorin SpA
- 13.15.1 Key Facts
- 13.15.2 Business Description
- 13.15.3 Products and Services
- 13.15.4 Financial Overview
- 13.15.5 SWOT Analysis
- 13.15.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms